{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:05:46Z","timestamp":1793912746847,"version":"4.8.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.metabol.2024.156004","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:56:50Z","timestamp":1724457410000},"page":"156004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["Metabolic dysfunction-associated steatotic liver disease and its link to cancer"],"prefix":"10.1016","volume":"160","author":[{"given":"Markos","family":"Kalligeros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0010","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0020","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0035","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2024.156004_bb0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"173","author":"Thomas","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0045","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity \u2013 a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0050","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.metabol.2024.156004_bb0055","series-title":"Liver cancer factsheet","first-page":"2022","author":"Organization WH","year":"2022"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0060","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0065","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156004_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.10.018","article-title":"The impact of NASH to liver transplantations with hepatocellular carcinoma in the United States","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2024.156004_bb0090","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.metabol.2024.156004_bb0095","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/liv.12903","article-title":"Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma","volume":"35","author":"Chettouh","year":"2015","journal-title":"Liver Int"},{"issue":"24","key":"10.1016\/j.metabol.2024.156004_bb0100","first-page":"11890","article-title":"Risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"27","author":"Guo","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0110","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0115","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","article-title":"Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study","volume":"79","author":"Ebrahimi","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0120","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.metabol.2024.156004_bb0125","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/hep4.2073","article-title":"Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers","volume":"6","author":"McHenry","year":"2022","journal-title":"Hepatol Commun"},{"issue":"18","key":"10.1016\/j.metabol.2024.156004_bb0130","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.22.01740","article-title":"Increased risk of young-onset digestive tract cancers among young adults age 20-39 years with nonalcoholic fatty liver disease: a nationwide cohort study","volume":"41","author":"Park","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1440-1746.2009.06117.x","article-title":"Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps","volume":"25","author":"Hwang","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/gut.2011.237974","article-title":"High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1756283X11402118","article-title":"Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease","volume":"4","author":"Touzin","year":"2011","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156004_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2018.06.004","article-title":"Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis","volume":"87","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.metabol.2024.156004_bb0155","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/jgh.15158","article-title":"High risk of colorectal polyps in men with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Chen","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12944-022-01659-1","article-title":"Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis","volume":"21","author":"Zeng","year":"2022","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12957-018-1461-z","article-title":"The combined effect of non-alcoholic fatty liver disease and metabolic syndrome on colorectal carcinoma mortality: a retrospective in Chinese females","volume":"16","author":"Chen","year":"2018","journal-title":"World J Surg Oncol"},{"issue":"21","key":"10.1016\/j.metabol.2024.156004_bb0170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033867","article-title":"Association between nonalcoholic fatty liver disease and colorectal cancer: a population-based study","volume":"102","author":"Wu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/apt.13866","article-title":"Non-alcoholic fatty liver diseases and risk of colorectal neoplasia","volume":"45","author":"Ahn","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0180","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"44","author":"Souza","year":"2024","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0185","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10552-018-1095-z","article-title":"Non-alcoholic fatty liver disease and colorectal cancer survival","volume":"30","author":"Wu","year":"2019","journal-title":"Cancer Causes Control"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0190","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.3390\/curroncol30110690","article-title":"Colorectal cancer in individuals with cirrhosis: a population-based study assessing practice patterns, outcomes, and predictors of survival","volume":"30","author":"Patel","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41420-023-01770-x","article-title":"Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.metabol.2024.156004_bb0200","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/hep.30693","article-title":"NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD","volume":"70","author":"Ohashi","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.metabol.2024.156004_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.04.013","article-title":"Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment","volume":"35","author":"Wang","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.156004_bb0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2020.00251","article-title":"Effect of non-alcoholic fatty liver disease on the risk of synchronous liver metastasis: analysis of 451 consecutive patients of newly diagnosed colorectal cancer","volume":"10","author":"Lv","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156004_bb0215","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/17474124.2019.1697231","article-title":"The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer","volume":"13","author":"Lv","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.metabol.2024.156004_bb0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jjco\/hyad038","article-title":"Metabolic-associated fatty liver disease and risk of esophagogastric cancer: a systematic review and meta-analysis","volume":"53","author":"Zou","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.metabol.2024.156004_bb0225","article-title":"Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study","volume":"56(11):1503","author":"Audrey","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226351","article-title":"The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: national population-based cohort study","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.metabol.2024.156004_bb0235","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doae029","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study","volume":"37","author":"Jeon","year":"2024","journal-title":"Dis Esophagus"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0240","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/hepr.13973","article-title":"Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: a multicenter study","volume":"54","author":"Fukunaga","year":"2024","journal-title":"Hepatol Res"},{"issue":"7","key":"10.1016\/j.metabol.2024.156004_bb0245","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jgh.15350","article-title":"The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development","volume":"36","author":"Yamamoto","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156004_bb0250","unstructured":"Nakane T, Fukunaga S, Nakano D, Tsutsumi T, Tanaka H, Chou T, et al. Impact of metabolic dysfunction-associated fatty liver disease on the incidence of Helicobacter pylori-negative gastric cancer. Hepatology Research.n\/a(n\/a)."},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0255","doi-asserted-by":"crossref","first-page":"10681","DOI":"10.1038\/s41598-022-14856-w","article-title":"Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease","volume":"12","author":"Park","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.metabol.2024.156004_bb0260","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1055-9965.EPI-23-0453","article-title":"Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: Mendelian randomization","volume":"32","author":"King","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15","key":"10.1016\/j.metabol.2024.156004_bb0265","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.ejca.2015.07.034","article-title":"Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999\u20132007: results of EUROCARE-5","volume":"51","author":"Lepage","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.metabol.2024.156004_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156004_bb0275","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2021.03.024","article-title":"Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: a South Korean nationwide cohort study","volume":"150","author":"Park","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0280","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12876-017-0696-4","article-title":"Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis","volume":"17","author":"Wongjarupong","year":"2017","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0285","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s11605-023-05794-7","article-title":"Postoperative prognosis of non-alcoholic fatty liver disease-associated intrahepatic Cholangiocarcinoma: a multi-center propensity score matching analysis","volume":"27","author":"Yu","year":"2023","journal-title":"J Gastrointest Surg"},{"issue":"7","key":"10.1016\/j.metabol.2024.156004_bb0290","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.dld.2018.12.024","article-title":"Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women","volume":"51","author":"Kwak","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"39","key":"10.1016\/j.metabol.2024.156004_bb0295","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017277","article-title":"Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery","volume":"98","author":"Lee","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.metabol.2024.156004_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201308","article-title":"Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.metabol.2024.156004_bb0305","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1136\/gutjnl-2022-328887","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer","volume":"72","author":"Roderburg","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156004_bb0310","series-title":"Hepatobiliary surgery and nutrition; vol 12, no 5 (October 01, 2023): hepatobiliary surgery and nutrition","article-title":"Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China","author":"Yuan","year":"2022"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.05.009","article-title":"Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China","volume":"19","author":"Wang","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0320","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad575","article-title":"Nonalcoholic fatty liver disease and the risk of thyroid cancer among young adults in South Korea","volume":"109","author":"Kwon","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156004_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.985858","article-title":"The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0330","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12020-023-03312-y","article-title":"Prevalence and impact of non-alcoholic fatty liver disease in patients with papillary thyroid carcinoma","volume":"80","author":"Xiao","year":"2023","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0335","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1038\/s41598-023-44243-y","article-title":"AST\/ALT-to-platelet ratio (AARPRI) predicts gynaecological cancers: a 8-years follow-up study in 653 women","volume":"13","author":"Crudele","year":"2023","journal-title":"Sci Rep"},{"issue":"37","key":"10.1016\/j.metabol.2024.156004_bb0340","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017098","article-title":"Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.metabol.2024.156004_bb0345","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156004_bb0350","article-title":"Molecular mechanisms in MASLD\/MASH-related HCC","author":"Wang","year":"2024","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.metabol.2024.156004_bb0355","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3390\/ijerph16183415","article-title":"NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome","volume":"16","author":"Rosato","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0360","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","article-title":"Hyperinsulinaemia in cancer","volume":"20","author":"Gallagher","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.metabol.2024.156004_bb0365","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.tem.2006.08.006","article-title":"Obesity and cancer risk: the role of the insulin\u2013IGF axis","volume":"17","author":"Renehan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2024.156004_bb0370","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tem.2010.06.007","article-title":"The proliferating role of insulin and insulin-like growth factors in cancer","volume":"21","author":"Gallagher","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"Supple 1","key":"10.1016\/j.metabol.2024.156004_bb0375","first-page":"S10","article-title":"Pathogenesis of MASLD and MASH\u2013role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.metabol.2024.156004_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082034","article-title":"NAFLD-Related Hepatocarcinoma: the malignant side of metabolic syndrome","volume":"10","author":"Michelotti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2024.156004_bb0385","article-title":"Adipokines and obesity. Potential link to metabolic disorders and chronic complications","volume":"21(10):3570","author":"Zorena","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.metabol.2024.156004_bb0390","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.3390\/ijms25084397","article-title":"The relationship between pathogenesis and possible treatments for the MASLD \u2212 cirrhosis spectrum","volume":"25","author":"Vidal-Cevallos","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"48","key":"10.1016\/j.metabol.2024.156004_bb0395","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Stojsavljevi\u0107","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.metabol.2024.156004_bb0400","article-title":"Obesity-induced chronic low grade inflammation: gastrointestinal and adipose tissue crosstalk","volume":"1(124):10.15761","author":"Magnuson","year":"2015","journal-title":"Integr Obesity Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0405","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4093\/dmj.2020.0250","article-title":"Hyperinsulinemia in obesity, inflammation, and cancer","volume":"45","author":"Zhang","year":"2021","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2024.156004_bb0415","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000479918","article-title":"Bacterial translocation from the gut to the distant organs: an overview","volume":"71","author":"Nagpal","year":"2017","journal-title":"Ann Nutr Metab"},{"issue":"8","key":"10.1016\/j.metabol.2024.156004_bb0420","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000068","article-title":"Dysbiosis of the duodenal mucosal microbiota is associated with increased small intestinal permeability in chronic liver disease","volume":"10","author":"Raj","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0425","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41575-018-0025-6","article-title":"Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer","volume":"15","author":"Cani","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156004_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.metabol.2024.156004_bb0435","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7659509","article-title":"Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease","volume":"2019","author":"Wang","year":"2019","journal-title":"Mediat Inflamm"},{"issue":"5","key":"10.1016\/j.metabol.2024.156004_bb0440","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0445","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hbpd.2018.11.002","article-title":"Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis","volume":"18","author":"Jiang","year":"2019","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.metabol.2024.156004_bb0450","doi-asserted-by":"crossref","first-page":"4797453","DOI":"10.1155\/2022\/4797453","article-title":"The gut-liver axis in nonalcoholic fatty liver disease: association of intestinal permeability with disease severity and treatment outcomes","volume":"2022","author":"Zhuang","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"46","key":"10.1016\/j.metabol.2024.156004_bb0455","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","article-title":"Role of Kupffer cells in the pathogenesis of liver disease","volume":"12","author":"Kolios","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0460","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/cas.16042","article-title":"Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype","volume":"115","author":"Tai","year":"2024","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0465","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep4.1822","article-title":"TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease","volume":"6","author":"Luo","year":"2022","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0470","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0475","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ijms19030911","article-title":"Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD)","volume":"19","author":"Del Campo","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0480","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156004_bb0485","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0490","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0495","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156004_bb0500","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.03.021","article-title":"Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity","volume":"161","author":"Rustgi","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.metabol.2024.156004_bb0505","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.metabol.2024.156004_bb0510","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2018.12.014","article-title":"Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study","volume":"70","author":"Baumeister","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0515","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.17308","article-title":"Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Henry","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0520","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0525","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.metabol.2024.156004_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.01.057","article-title":"Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease","volume":"21","author":"Zou","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.metabol.2024.156004_bb0535","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.14309\/ajg.0000000000001347","article-title":"Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis","volume":"116","author":"Pinyopornpanish","year":"2021","journal-title":"Am Coll Gastroenterol"},{"issue":"9","key":"10.1016\/j.metabol.2024.156004_bb0540","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17474124.2022.2119128","article-title":"Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals","volume":"16","author":"Ng","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0545","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"Kramer","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.metabol.2024.156004_bb0550","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156004_bb0555","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.metabol.2024.156004_bb0560","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41575-024-00907-2","article-title":"Screening for liver fibrosis: lessons from colorectal and lung cancer screening","volume":"21","author":"Thiele","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156004_bb0565","doi-asserted-by":"crossref","unstructured":"Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology 9900:https:\/\/doi.org\/10.1097\/HEP.0000000000000843.","DOI":"10.1097\/HEP.0000000000000843"},{"issue":"4","key":"10.1016\/j.metabol.2024.156004_bb0570","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.metabol.2024.156004_bb0575","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.metabol.2024.156004_bb0580","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156004_bb0585","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/637538","article-title":"The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome","volume":"2012","author":"Muhidin","year":"2012","journal-title":"J Obes"},{"issue":"3","key":"10.1016\/j.metabol.2024.156004_bb0590","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/liv.15832","article-title":"Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: a nationwide cohort study","volume":"44","author":"Park","year":"2024","journal-title":"Liver Int"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:07:49Z","timestamp":1732666069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524002312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":118,"alternative-id":["S0026049524002312"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156004","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156004"}}